Consensus Repligen Corporation

Stocks

RGEN

US7599161095

Medical Equipment, Supplies & Distribution

Real-time Estimate Cboe BZX 19:15:16 30/09/2026 BST			5-day change	1st Jan Change
195.18 ^USD	+0.31%		+5.48%	+18.79%

09-15	Repligen Corporation Announces Retirement of Karen A. Dawes from Board of Directors, Effective September 30, 2026	CI
09-09	Repligen Corporation Presents at Wells Fargo 21st Annual Healthcare Conference, Sep-09-2026 01:30 PM

Evolution of the Average Target: Repligen Corporation

Evolution of the Target Price: Repligen Corporation

Changes in Analyst Recommendations: Repligen Corporation

f9e0731fbc.Cebh266AbnVOFw756hR24Pi4wunDcFRsz1cmTLxnekI.RYynlJnJJxM2f0Ox20sR1I-VipOKGjIZvyJVOPBQHjBf0Kma5e4jGn19Sw~5e39be2261dcaf30274b0ef2efab00ce

Analysts' recommendations: Repligen Corporation

09-09	UBS Adjusts Price Target on Repligen to $225 From $195, Keeps Buy Rating	MT
09-01	Analyst recommendations: Duolingo, Robinhood, Adobe, CrowdStrike, Salesforce…
07-29	Repligen's Diversity of Growth Drivers Support Return to Mid-Teens Organic Sales Growth, RBC Says	MT
07-29	RBC Raises Price Target on Repligen to $185 From $160, Keeps Outperform Rating	MT
07-29	Deutsche Bank Adjusts Repligen Price Target to $200 From $180, Maintains Buy Rating	MT
07-07	Benchmark Upgrades Repligen to Buy From Hold, Price Target is $185	MT
05-15	Repligen Likely to Benefit From Diverse Growth Factors, RBC Says	MT
04-17	Rothschild & Co Redburn Initiates Repligen at Buy With $160 Price Target	MT
02-25	UBS Adjusts Price Target on Repligen to $195 From $200, Maintains Buy Rating	MT
01-16	UBS Adjusts Price Target on Repligen to $200 From $190, Maintains Buy Rating	MT
01/10/25	HSBC Initiates Repligen at Buy With $150 Price Target	MT
22/09/25	Repligen Shares Rise After Upgrade From Evercore ISI	MT
22/09/25	Evercore ISI Upgrades Repligen to Outperform From In Line, Price Target is $155	MT
03/09/25	RBC Lifts Price Target on Repligen to $205 From $204, Keeps Outperform Rating	MT
30/07/25	RBC Raises Price Target on Repligen to $204 From $193, Keeps Outperform Rating	MT
29/07/25	Life sciences firm Repligen beats Q2 revenue estimates, raises full-year guidance	RE
01/07/25	RBC Lifts Price Target on Repligen to $193 From $191, Keeps Outperform Rating	MT
24/06/25	Barclays Initiates Repligen at Overweight With $150 Price Target	MT
30/04/25	RBC Lowers Price Target on Repligen to $189 From $202, Keeps Outperform Rating	MT
29/04/25	Wolfe Research Upgrades Repligen to Outperform From Peerperform	MT
08/04/25	RBC Cuts Price Target on Repligen to $202 From $219, Keeps Outperform Rating	MT
18/03/25	Evercore ISI Initiates Repligen at In Line With $155 Price Target	MT
21/02/25	RBC Raises Price Target on Repligen to $205 From $203, Keeps Outperform Rating	MT
21/02/25	Deutsche Bank Adjusts Repligen Price Target to $195 From $190, Maintains Buy Rating	MT
10/02/25	TD Cowen Initiates Repligen at Buy With $200 Price Target	MT

More recommendations

Other Medical Equipment, Supplies & Distribution

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	REPLIGEN CORPORATION					-2.5%
	ABBOTT LABORATORIES					+19.13%
	MEDTRONIC PLC					+20.37%
	STRYKER CORPORATION					+31.94%
	ESSILORLUXOTTICA					+61.01%
	CENCORA, INC.					+20.04%
	BECTON, DICKINSON AND COMPANY					+7.53%
	HOYA CORPORATION					+30.03%
	IDEXX LABORATORIES, INC.					+31.47%
	DEXCOM, INC.					+9.05%
	Average					+22.81%
	Weighted average by Cap.					+25.64%